In addition to providing tremendous marketing and commercial potential, China offers unique and significant opportunities for R&D marked by:
- Vast patient population
- A rapidly improving regulatory environment
- Highly trained scientists and investigators
- Qualified clinical trial sites
- Established CRO/CMO support
These benefits translate into shorter patient enrollment time, faster data gathering and early entry into the market. Our seasoned team leverages these growing opportunities while developing drugs for the Chinese market in a timely and cost-effective manner.
Our current focus is on licensing drugs in China, which originated in other markets, and developing these highly effective medications to address the unmet medical needs of China. Our key objective is to leverage our experiences and resources in China to bring value to our partners, investors, and potential patients.